Evidence map›Paper›PMID 40895557›Full record

ReviewFrontiers in immunology2025

Relapsing polychondritis following PD-1 blockade diagnosed via 18F-FDG PET/CT and improved by steroid administration: a case report and literature review.

Ruo-Wen Xu, Wen-Bo Dong, Yong-Xu Wang, Yong-Qi Liu, Chen Chen, Wei Wang, Hai-Na Liu, Hong-Yu Jin, Wen-Yang Li

Abstract readCase ReportsReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Ruo-Wen Xu *Respiratory and Critical Care Department, The First Hospital of China Medical University, Shenyang, China.
Wen-Bo Dong *First Clinical College, China Medical University, Shenyang, China.
Yong-Xu Wang *Respiratory and Critical Care Department, The First Hospital of China Medical University, Shenyang, China.
Yong-Qi Liu *Respiratory and Critical Care Department, The First Hospital of China Medical University, Shenyang, China.
Chen Chen *Respiratory and Critical Care Department, The First Hospital of China Medical University, Shenyang, China.
Wei WangRespiratory and Critical Care Department, The First Hospital of China Medical University, Shenyang, China.
Hai-Na LiuDepartment of Rheumatology and lmmunology, The First Affiliated Hospital of China Medical University, Shenyang, China.
Hong-Yu JinRespiratory and Critical Care Department, The First Hospital of China Medical University, Shenyang, China.
Wen-Yang LiRespiratory and Critical Care Department, The First Hospital of China Medical University, Shenyang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Up to 22% of cancer patients treated with immune checkpoint inhibitors (ICIs) can experience immune-related adverse events (irAEs) that mimic rheumatic disease, such as relapsing polychondritis (RP), which is a rare autoimmune disease that mainly manifests as inflammation of airway cartilage. Methods: We report a case of RP induced by humanized recombinant anti-PD-1 monoclonal antibody therapy (tislelizumab). 18F-Fluorodeoxyglucose positron emission tomography/ computed tomography (18F-FDG PET/CT) contributed to the diagnosis of RP, and methylprednisolone was used to effectively control its progression. We also reviewed 13 publications on drug-induced RP in the context of cancer and analyzed the pathogenesis, ancillary tests, treatment, and prognosis of the cases described therein. Results: Including our case, 14 drug-related RP cases with a tumor background were analyzed. Patients usually develop related symptoms 3-5 months after initiating medication. The primary tumor involvement sites included the hematological system (5/14, 35.71%), upper digestive tract (4/14, 28.57%), skin (2/14, 14.29%), reproductive system (2/14, 14.29%), bone (1/14,7.14%), and lung (1/ 14, 7.14%). Conclusion: 18F-FDG PET/CT plays a crucial role in diagnosing RP caused by PD-1 monoclonal antibodies. Early detection and the prompt administration of corticosteroids are crucial in effectively controlling the progression of RP, helping to alleviate symptoms and prevent further complications.

Indexed as

Antibodies, Monoclonal, HumanizedImmune Checkpoint InhibitorsMethylprednisolonePolychondritis, RelapsingPositron Emission Tomography Computed TomographyProgrammed Cell Death 1 ReceptorFluorodeoxyglucose F18HumansTreatment OutcomeAntibodies, Monoclonal, HumanizedFluorodeoxyglucose F18Immune Checkpoint InhibitorsMethylprednisolonePDCD1 protein, humanProgrammed Cell Death 1 Receptortislelizumab18F-FDG PET/CTcancerICI-induced RPimmune-related adverse eventsPD-1 blockaderelapsing polychondritis

Identifiers

PMID40895557
PMCPMC12391198

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.